Background and aims: Whether inflammatory bowel disease [IBD] is associated with specific psoriasis phenotypes is undefined. In a case-control prospective study, we aimed to assess the severity and phenotype of psoriasis in IBD vs matched non-IBD controls with psoriasis [non-IBD] 
psoriasis is associated with joint disease, known as psoriatic arthritis, although this condition has been reported to be a different entity with a distinct therapeutic spectrum. 2 Since the 1960s, psoriasis has been associated with inflammatory bowel disease [IBD] in terms of epidemiology, pathogenesis, and genotype. 3, 4 Common clinical and immunological features have indeed been described in IBD and psoriasis, probably due to shared susceptibility genes observed in genome-wide association studies. 5 The interleukin-23 pathway has indeed been similarly involved in the pathogenesis of IBD, psoriasis and psoriatic arthritis, even if multiple genes can regulate these pathways. 6 The prevalence of psoriasis in patients with Crohn's disease [CD] has been shown to be higher than in non-IBD controls [9.6% vs 2.2%, p < 0.02], with a higher prevalence in CD than in ulcerative colitis [UC] patients [11.2% vs 5.7% with odds ratios [OR] at multivariate analysis of 2.49 and 1.64, respectively]. 4, 7, 8 Recently, several independent observations described the appearance of psoriatic eruptions in IBD patients treated with anti-tumour necrosis factor-α [anti-TNFα] treatments. 9, 10 Psoriatic lesions indeed represent the most frequent dermatological adverse event in patients receiving anti-TNFα treatments, as reported by rheumatological studies. 11, 12 A main mechanism able to determine the development of psoriatic lesions after anti-TNFα treatments has been suggested. 6 Interferon-α [IFN-ɑ] production from dendritic cells, observed in psoriatic lesions, is inhibited by TNFα. 6 Therefore, blocking TNFα by using anti-TNFα treatments increases the production of IFN-ɑ, thus inducing worsening or new appearance of psoriatic lesions. 6 Most patients showing psoriasis after anti-TNFα treatments appear to have no previous history of psoriatic lesions. Several studies also investigated the possible relationship between the development of psoriasis and clinical characteristics of IBD in patients not treated with anti-TNFα [i.e. phenotype, IBD activity, family history of IBD, smoking, age]. 13 No definite association has been described in this regard.
Whether IBD is associated with specific phenotypes of psoriasis 14 is currently undefined. On the basis of these observations, the aim of the present study was to assess, in a case-control prospective study, the severity and phenotype of psoriasis in patients with IBD, when compared with non-IBD controls with psoriasis [non-IBD] matched for clinical variables.
Materials and Methods

Study design
From January 2011 to November 2013, all IBD patients under regular follow-up at our tertiary IBD centre and requiring dermatological assessment were prospectively referred to a dedicated dermatologist from the same university/hospital. In particular, in a prospective case-control study, dermatological assessment was scheduled by the IBD-dedicated gastroenterologist after routine clinical assessment for IBD. Indication for a dermatological assessment included any skin lesion reputed by the IBD-dedicated gastroenterologist to deserve further characterisation, classification, and management. For a proper evaluation of psoriasis phenotype in IBD, each IBD patient with psoriasis was prospectively matched for gender, ethnicity, and age [± 5 years] with one non-IBD patient with psoriasis, referring to the same dedicated dermatological unit.
Study population: IBD patients
The IBD group included patients with a diagnosis of CD or UC, defined according to current guidelines. 15 For each patient, clinical 15, 16 ; 2] regular follow up at our referral IBD centre; 3] compliance with dermatological assessment; 4] indication for dermatological assessment, given by the IBD-dedicated gastroenterologist in relation to the presence of any type of skin lesion, including psoriasis, deserving further evaluation; 5] available demographic and clinical characteristics reported in clinical records.
Study population: non-IBD patients
The non-IBD group included patients with a known diagnosis of psoriasis and no IBD. In order to ensure that the control group had no IBD, all control patients were selected after an accurate present and past medical history had excluded any sign or symptom compatible with either UC or CD [i.e. abdominal mass, perianal disease, other fistulae, erythema nodosum, pyoderma gangrenosum]. The absence of persisting haematochemical alterations compatible with chronic inflammation, as observed in subgroups of patients with IBD, was also a criterion. Due to the absence of clinical history, signs, symptoms, and blood chemistry alterations suggesting a previously unknown diagnosis of IBD, diagnostic procedures aiming to exclude IBD were considered not appropriate.
Non-IBD patients were enrolled according to the following inclu- 
IBD patients and psoriasis
Clinical characteristics of IBD patients with and without psoriasis
The frequency and characteristics of psoriasis in patients with IBD patients and, separately, in patients with UC, CD, and non-IBD, are summarised in Table 3 summarises the psoriasis severity and phenotype in the 62 IBD patients and in the 62 matched non-IBD controls with psoriasis. Among the 62 IBD patients, the frequency of mild psoriasis was higher than the frequencies of both moderate and severe psoriasis [p < 0.0001 for both]. The frequency of moderate psoriasis was higher than the frequency of severe psoriasis [p < 0.0001]. Among the 62 non-IBD patients with psoriasis, the frequency of severe psoriasis was lower than the frequency of both mild and moderate psoriasis [p < 0.0001 for both]. When comparing the severity of psoriasis in IBD vs non-IBD groups, mild psoriasis [ Figure 1 ] was detected in a higher proportion of IBD patients [p < 0.0001] [ Table 3 ]. On the other hand, moderate psoriasis and severe psoriasis were more frequent in non-IBD than in IBD patients [p = 0.004 and p = 0.036, respectively] [ Table 3 ]. The frequencies of mild and moderate psoriasis were also significantly higher in non-IBD vs UC patients [p = 0.001 and p = 0.011, respectively] [ Table 3 ]. As for UC, when comparing the severity of psoriasis between CD and non-IBD patients, the frequencies of moderate and severe psoriasis were higher in non-IBD [p = 0.057], whereas the frequency of mild psoriasis was higher in CD patients [p = 0.005]. On the other hand, the frequencies of mild, moderate, and severe psoriasis were comparable between CD and UC patients [p = non-significant]. Figure 2 shows a case of severe diffuse plaque type psoriasis in a non-IBD patient.
Psoriasis phenotype in IBD and non-IBD controls
When considering psoriasis phenotype, plaque type psoriasis [ Figure 1 ] was the most common phenotype in both IBD and non-IBD patients [p < 0.0001 vs sebopsoriasis, guttate, pustular, scalp, nail, and palmo-plantar for both groups][ Table 3 ]. Figures 3 and 4 show the presence of skin lesions related to sebopsoriasis in three patients with CD, and Figure 5 shows nail psoriasis in one patient with CD.
However, when comparing the frequency of psoriasis phenotypes in IBD vs non-IBD, a significantly lower frequency of plaque-type psoriasis was observed in our tested IBD vs non-IBD population Figure 7 ], sebopsoriasis [1] and inverse psoriasis [1] . Among these 6 CD patients, 4 developed psoriasis after IFX and 2 after ADA. When considering the 4 patients with psoriasis after IFX, complete resolution was observed in 2, by using topical steroids in 1 patient, and after discontinuation of IFX, followed by CyS and MTX, in the second patient. The remaining 2 patients showed no resolution after IFX discontinuation and topical steroids. Among the 2 patients with psoriasis occurring after ADA, no resolution has currently been observed after ADA discontinuation, followed by CyS treatment in 1 patient. 
Non-psoriatic skin manifestations in IBD patients
Discussion
The association between psoriasis and IBD has been described since the 1960s. 3, 4 Recently, the growing use of anti-TNFα treatments hasled to the unexpected observation that, although targeting TNFα shows efficacy for treating psoriasis, anti-TNFα may also induce the development or relapse of psoriasis in patients with IBD. The possible development of psoriasis in IBD patients treated with anti-TNFα 10 raised new interest regarding the possible relationship between psoriasis and IBD. Several studies investigated this issue, 17 including possible pathogenic mechanisms leading to psoriasis after anti-TNFα treatments in IBD. A role for IFNα 6, 18 and IL-21 has been suggested. 19 Despite these evidences, to our knowledge no studies specifically investigated whether IBD is associated with specific characteristics of psoriasis [i.e. phenotype and severity], irrespective of anti-TNFα treatments. On the basis of these observations, in a prospective study we aimed to address this issue by comparing the phenotype and severity of psoriasis in a consecutive series of IBD patients and non-IBD controls matched for clinical and demographic characteristics.
In our IBD population, almost one-fourth [25%] of patients had a diagnosis of psoriasis, with a comparable frequency in CD and UC. The observed high frequency of psoriasis in our study is explained by the tested IBD population, including only the subgroup of IBD patients referred to the dermatologist, due to skin lesions requiring further characterisation or for screening before IMM treatments. This observation accounts for the high proportion of IBD patients with a diagnosis of psoriasis in our study population. The aim of the present study was indeed to characterise the clinical characteristics of psoriasis in IBD vs non-IBD controls and not to assess the frequency of psoriasis in IBD.
According to current literature, 20, 21 in our study population, clinical characteristics of IBD [site, extent, duration] appeared not to influence the frequency of psoriasis in either CD or UC. Clinical and demographic characteristics of tested UC and CD populations were comparable, with the exclusion of patients' age being higher in the UC vs the CD group. Nevertheless, the observed comparable frequency of psoriasis between UC and CD patients with or without psoriasis supports the observation that age did not significantly affect our findings. In our study, IBD patients and non-IBD controls were matched for demographic characteristics, thus allowing a proper comparison in terms of frequency, severity, and phenotype of psoriasis.
The main finding of the present study is that, when comparing the severity of psoriasis in IBD vs matched non-IBD controls, IBD patients showed a significantly higher frequency of mild psoriasis. Accordingly, IBD patients also showed a significantly lower frequency of both moderate and severe psoriasis compared with non-IBD controls. It is conceivable that corticosteroids, thiopurines, and/ or anti-TNFα used for treating patients with IBD, may play a role in this finding, as these treatments may reduce the severity of the psoriatic lesions. 22, 23, 24 This is also supported by the observation that the frequency of mild, moderate, or severe psoriasis was comparable between patients with CD and UC. Whether the observed lower frequency of moderate/severe psoriasis in our IBD population is also observed in the general IBD population needs to be confirmed by larger studies, also in relation to the possible role played by different treatments used for IBD when considering different study populations. Although IBD, especially CD, can be asymptomatic and sometimes psoriasis can precede the diagnosis of CD, control patients were selected on the basis of a complete absence of present or past medical history, signs/symptoms, or blood chemistry alterations suggesting IBD. Due to the absence of any clinical indication, no additional diagnostic tests were performed in order to exclude IBD.
The second main message arising from our study is that, when comparing psoriasis phenotypes, IBD patients showed a significantly lower frequency of plaque-type, nail, and psoriatic arthritis when compared with non-IBD patients. Explanations for these findings, as also the possible pathogenic mechanisms leading to this observation in our IBD population, are currently not defined. Whether some of the immunological mechanisms involved in the pathogenesis of psoriasis [i.e. IL-23] may play a role in the observed different psoriasis phenotypes in our IBD and non-IBD populations, cannot be addressed in the present study. The aim of the study was indeed to initially assess the severity and phenotype of psoriasis in IBD vs matched non-IBD controls and not to address possible pathogenic mechanisms leading to these findings. Data on invasive skin biopsies and/or cytokine levels assessment were therefore considered not useful as a first step. However, the observed differences between IBD and non IBD patients developing psoriasis support the need for future epidemiological and in vitro studies to confirm and to further investigate this topic.
To our knowledge, no comparisons can ibe made with previous observations, as data in this regard are lacking.
When considering psoriasis phenotype, plaque-type psoriasis represented the most frequent phenotype in both IBD and non-IBD study populations. This finding is in agreement with current literature, supporting the conclusion that plaque-type psoriasis is the more frequent phenotype in the general non-IBD population, 25 thus supporting the reliability of dermatological assessment in our study.
In our study, the tested IBD population represented only a proportion of IBD patients evaluated by IBD-dedicated gastroenterologists during the study period [only IBD patients with skin lesions]. This subgroup analysis could represent a limit of the present study. However, two main observations support the contention that the tested IBD population is representative of the general IBD population. In particular, according to current literature, 26 the frequency of psoriasis was significantly higher in UC patients with a family history of psoriasis, although in CD patients this difference did not reach statistical significance. Moreover, characteristics of IBD patients appeared not to influence the frequency of psoriasis in our IBD population. This observation also is supported by current knowledge at this regard, 26 further suggesting the reliability of both the tested IBD population and the modality of dermatological assessment. Regarding the frequency, phenotype and severity of psoriasis in IBD patients treated with anti-TNFα, no conclusions can be drawn from the present study. In our series, psoriasis after anti-TNFα was indeed observed in only 6 of the 68 [9%] patients in CD and in none of the 21 [0%] patients with UC treated with anti-TNFα. Nevertheless, present findings indicate a quite high frequency of psoriasis developing after anti-TNFα treatments in patients with CD, in agreement with previous studies. 26 Present findings also suggests the need to further address this issue, due to the observed arduous clinical management when treating psoriasis developing after anti-TNFα treatment. Present observations also further support a multidisciplinary approach to increase the quality of care of patients with IBD, as a dermatological evaluation may lead to a new diagnosis or to a detailed characterisation of skin lesions not properly assessed by IBD-dedicated gastroenterologists.
In conclusion, the present prospective case-control study showed a lower frequency of severe psoriasis in tested the IBD population. A lower frequency of plaque-type psoriasis, nail psoriasis, and psoriatic arthritis was also observed in tested IBD vs non-IBD populations. The reported observations may provide new evidences regarding the characteristics of psoriasis in IBD, including severity and phenotype, at least in our IBD population. Present findings may also add new clues useful for further studies focusing on the pathogenic mechanisms leading to psoriasis in patients with IBD, regardless of current or past use of anti-TNFα treatments. The growing evidences supporting the possible development of psoriasis in IBD patients treated with anti-TNFα indicate that psoriasis represents a currently relevant issue, in terms of pathogenic mechanisms and clinical management of patients with IBD.
